|Day Low/High||26.58 / 27.08|
|52 Wk Low/High||14.81 / 42.17|
Portola Pharmaceuticals (PTLA) stock is dropping late Monday afternoon as Goldman Sachs downgraded the stock and the company reported disappointing trial results last week.
Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a weak on high relative volume candidate
Portola Pharmaceuticals (PTLA) stock is tumbling on heavy trading volume on Thursday afternoon the company said its oral treatment for blood clots is not statistically different than the current standard.
Portola Pharmaceuticals (PTLA) stock is down after the company said its oral treatment for blood clots was not statistically different than the current standard of care.
Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a pre-market mover with heavy volume candidate
Doug Kass shares his views on why technicals bode ill for tech.
Conference Call Today at 8:30 a.m. ET
--Target FDA Action Date is August 17, 2016--
Doug Kass shares his views on the health of the banking sector and why he's buying biotech.
Portola Retains Full Worldwide Commercial Rights to Andexanet Alfa Outside of Japan
Two Products in Thrombosis Franchise Expected to Launch in Next 18 Months
These stocks look poised to break out and trade higher from current levels.
Full Data Set From ANNEXA-R Also Presented Today in Late-Breaking Clinical Trial Session at AHA Scientific Sessions 2015
Full Results of Andexanet Alfa and Rivaroxaban Part 2 Study to be Featured in Late-Breaking Clinical Trial Oral Session on November 11th
Betrixaban Has Potential to Become First Oral Factor Xa Inhibitor Anticoagulant Approved for Hospital-to-Home Prevention of Venous Thromboembolism in Acute Medically Ill Patients
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.